Addex Shareholders Appoint Raymond Hill and Tim Dyer to the Board of Directors and approve all Board Proposals at Annual General Meeting
June 12, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 12 June 2015 -...
Addex Identifies New Potential Use of mGlu7 receptor NAMs to Treat Stress-Induced Visceral Pain
June 03, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland 3 June 2015 -...
Addex and Prof. Pisani Present Dipraglurant data in Rare Inherited Forms of Dystonia
May 29, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
5th Biennial Workshop on Dystonia...
Addex Annual General Meeting Scheduled for 11 June 2015
May 27, 2015 09:50 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland 27 May 2015 -...
Addex Enters Collaboration with Prof. Pisani to Explore the Therapeutic use of Dipraglurant in the Treatment of Rare Inherited Forms of Dystonia
May 07, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
...
Addex Therapeutics Reports 2014 Financial Results
April 30, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
2014 Financial Highlights Increased...
Addex Raises CHF2.8 million in a Private Placement and Extends Cash Runway Through 2017
March 09, 2015 02:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 9 March 2015 -...
Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation
February 23, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 23 February 2015...
Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death
February 19, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland, 19 February 2015...
Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia
January 19, 2015 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland /Chicago, USA, 19...